Summary
This research program is testing new medicines that target a specific group of cancer mutations called RAS mutations, which are common in several cancers, including non-small cell lung cancers. The goal is to find out how safe these new medicines are, how the body processes them, and whether they help shrink or control cancer.
The study is a platform trial, which means several related treatment plans (called subprotocols) can be tested under one main study. This allows researchers to compare different combinations of treatments more efficiently.
People can join the study if their cancer has a KRAS or RAS mutation, depending on the specific subprotocol.
Subprotocol A
- Testing the drug RMC-6291, with or without RMC-6236, together with pembrolizumab immunotherapy, with or without chemotherapy.
- For people with advanced solid cancers that have a KRAS G12C mutation.
Subprotocol B
- Testing RMC-6236 with pembrolizumab, with or without chemotherapy.
- For people with RAS-mutated non-small cell lung cancer.
Subprotocol C
- Testing RMC-9805, with or without RMC-6236, in combination with other cancer treatments.
- For people with RAS G12D-mutated non-small cell lung cancer.
Subprotocol D
- Testing Zoldonrasib (RMC-9805) alone.
- For people with RAS G12D-mutant non-small cell lung cancers who have already received previous treatments.
Study structure
Subprotocols A, B and C each have:
- Part 1: Finding the best dose
- Part 2: Treating more patients at that dose to learn more about safety and effectiveness
Subprotocols D has one part only, focusing on how well the treatment works in previously treated patients.